Issue 3

September 2015 | View PDF

S. Hedayatnia, and D. B. Giddon

A Business Case for Oral Physicians: Market Analysis and Potential Practice Models for Dentists to Address the United States Primary Care Shortage

Dentists are in a prime position to address the US primary care shortage by expanding their scope of practice towards screening for systemic health conditions. Primary care activity by dentists alone has the potential to save $15 billion in avoided medical expenses through concierge models and/or ACO- partnered dental practices.


P. K. Srivastava

Preventing Stroke in Atrial Fibrillation: Warfarin vs. Factor Xa Inhibitors

Warfarin has traditionally been used to prevent stroke in patients with atrial fibrillation. The advent of factor Xa inhibitors, however, has provided an alternative. This article evaluates the literature on factor Xa inhibitor use in patients with atrial fibrillation and discusses the general benefits and risks of this novel class of anticoagulants.


D. T. Wong, et al.

Historical Path of Discovery of Viral Hepatitis

This article presents an overview of the historical timeline of the gradual discovery of various hepatitis viruses and the pivotal roles of epidemiological observations, human experimentations, and laboratory research in their discovery and containment.


G. Baffy

Alma Mater Revisited: Teaching Medicine as a Fulbright Scholar

The prestigious Fulbright Program sends US grantees to teach or conduct research in over 155 countries. A Fulbright scholar from Harvard summarizes his recent teaching experience at a medical school in Hungary, where he graduated over 30 years ago. The one-semester fellowship provided meaningful lessons in developing and delivering a course on obesity to an internationally diverse group of students.


J. Panchalingam

Increasing Drug Costs in the United States: Time for Reform?

The ever-increasing burden of US healthcare costs—currently 18% of GDP—remains a priority for policymakers, as illustrated by the numerous efforts that have been initiated to reduce costs. However, relatively little attention has been paid to the relationship between drug approval processes or pricing strategies and the cost of drugs in the US, currently the highest in the world. Given the significant potential for cost savings in this field, federal legislation could play an important role in pharmaceutical regulation. Here, we will discuss cost-effectiveness criteria and their potential for introduction into the US drug approval process.


J. Fortunato

The “Harm Principle” in the Context of Organ Donation

Concern has arisen that “Donation after Circulatory Death” organ donors are not beyond harm; they may feel pain during procurement. A “harm principle,” which simply places the prevention of donor harm as a central ethical obligation, should be used during organ donation to protect donor interests and protect donors from physical suffering.